Isotoxic dose escalation for lung cancer radiotherapy using ABC.
Research type
Research Study
Full title
Iso-toxic Accelerated Radiotherapy and Deep Inspiration Breath-Hold with Active Breathing Control (ABC) Device in Non-Small-Cell Lung Cancer (NSCLC): A modeling study.
IRAS ID
160498
Contact name
Hannah Bainbridge
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Current British Phase 2 trials are investigating the role of isotoxic dose escalation radiotherapy (increasing the dose of radiotherapy to the cancer whilst keeping the dose of radiation the same to surrounding normal tissues) in patients with lung cancer. Standard radiotherapy is delivered using 4D radiotherapy which is a technique whereby tumour movement is tracked during the breathing cycle and radiotherapy fields are adjusted to accommodate all possible areas of tumour movement. An alternative technique is to use activated breathing control (ABC) which is a technique where patients hold their breath for 15-20 seconds (as tolerated). A CT scan is then done in moderate breath holding and this means that when we give the radiotherapy treatment the area we are trying to treat is stationary, so we can be more precise with the volume of tissue we are irradiating. Any radiotherapy (high dose x-ray treatment) that we give has to travel through normal tissue to get to the cancer. Normal tissue can only tolerate a certain dose of radiotherapy, and so this limits the amount of dose we can give to the cancer. We are hoping that with the use of ABC we can show that we can deliver a higher dose of radiotherapy to the cancer, whilst keeping the normal lung tissue dose the same, and in so doing increase the chance of controlling the cancer without compromising normal tissues.
REC name
London - Westminster Research Ethics Committee
REC reference
15/LO/0859
Date of REC Opinion
2 Jun 2015
REC opinion
Favourable Opinion